Cargando…

Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling

OBJECTIVE: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. METHODS: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bridges, John FP, Beusterien, Kathleen, Heres, Stephan, Such, Pedro, Sánchez-Covisa, Joaquín, Nylander, Anna-Greta, Chan, Elcie, de Jong-Laird, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757991/
https://www.ncbi.nlm.nih.gov/pubmed/29379273
http://dx.doi.org/10.2147/PPA.S152870
_version_ 1783290926993506304
author Bridges, John FP
Beusterien, Kathleen
Heres, Stephan
Such, Pedro
Sánchez-Covisa, Joaquín
Nylander, Anna-Greta
Chan, Elcie
de Jong-Laird, Anne
author_facet Bridges, John FP
Beusterien, Kathleen
Heres, Stephan
Such, Pedro
Sánchez-Covisa, Joaquín
Nylander, Anna-Greta
Chan, Elcie
de Jong-Laird, Anne
author_sort Bridges, John FP
collection PubMed
description OBJECTIVE: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. METHODS: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. RESULTS: Across 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151). CONCLUSIONS: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.
format Online
Article
Text
id pubmed-5757991
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57579912018-01-29 Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling Bridges, John FP Beusterien, Kathleen Heres, Stephan Such, Pedro Sánchez-Covisa, Joaquín Nylander, Anna-Greta Chan, Elcie de Jong-Laird, Anne Patient Prefer Adherence Original Research OBJECTIVE: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. METHODS: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. RESULTS: Across 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151). CONCLUSIONS: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement. Dove Medical Press 2018-01-04 /pmc/articles/PMC5757991/ /pubmed/29379273 http://dx.doi.org/10.2147/PPA.S152870 Text en © 2018 Bridges et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed
spellingShingle Original Research
Bridges, John FP
Beusterien, Kathleen
Heres, Stephan
Such, Pedro
Sánchez-Covisa, Joaquín
Nylander, Anna-Greta
Chan, Elcie
de Jong-Laird, Anne
Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling
title Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling
title_full Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling
title_fullStr Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling
title_full_unstemmed Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling
title_short Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling
title_sort quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757991/
https://www.ncbi.nlm.nih.gov/pubmed/29379273
http://dx.doi.org/10.2147/PPA.S152870
work_keys_str_mv AT bridgesjohnfp quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling
AT beusterienkathleen quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling
AT heresstephan quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling
AT suchpedro quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling
AT sanchezcovisajoaquin quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling
AT nylanderannagreta quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling
AT chanelcie quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling
AT dejonglairdanne quantifyingthetreatmentgoalsofpeoplerecentlydiagnosedwithschizophreniausingbestworstscaling